We read with interest the article by Robinson et al. reporting cross-reacting and specific epitopes on the flagellar protein of Borrelia burgdorferi (5) . The authors have overlooked previous findings, including our own study, which precisely characterized the common and specific epitopes of the flagellar protein by using overlapping decapeptides (6) and which have been confirmed since by others using recombinant fragments (1, 3) . This is especially unfortunate because the authors thus did not realize that they interrupted the integrity of the N-and C-terminal cross-reacting epitopes (6) by their choice of fragments (5) . In addition, by sera being preabsorbed with Escherichia coli cell sonicate (5), which is not done in routine diagnostic studies, potential crossreacting antibodies were excluded from their study, despite known sequence homologies between the flagellin of E. coli and that of B. burgdorfeni (2) . Furthermore, the unspecific binding of immunoglobulins to a region between amino acids (aa) 49 and 68 is already known (6) and can be blocked by preincubation with ovalbumin (4, 6 Our serological evaluation of the cloned full-length B. burgdorferi flagellin and selected regions indicated that syphilitic and normal sera reactive with the full-length protein also were reactive with either the amino-terminal (pl-137) or the carboxyl-terminal (p262-336) region but not with the central region. We believe that these data agree with the data of Schneider et al. The shared overlap between peptide amino acids 121 to 148 and fragment pl-137 and that between peptide amino acids 255 to 280 and fragment p262-336 are regions of high homology with the T. pallidum flagellin and may explain the immunological cross-reactivity of syphilitic and normal sera with these sequences.
The inclusion of the Escherichia coli sonicate in the serum dilution buffer was not included to preabsorb antibodies directed to E. coli flagellar proteins which might cross-react with B. burgdorfen flagellin. Rather, the sonicate was included as a precaution to absorb antibodies reactive with the CMP-2-keto-3-deoxyoctulosonic acid synthetase portion of the fusion protein or contaminating E. coli proteins or lipopolysaccharide remaining after the purification of the recombinant proteins. Experiments performed with crossreactive sera demonstrated that the added sonicate did not play a major role in improving assay specificity. Also, note that the B. burgdorferi flagellin region p137-262 displays only limited homology with E. coli flagella, similar to that of T. pallidum (4) .
We previously demonstrated that the flagellin-specific monoclonal antibody H9724 reacted with a synthetic peptide representing amino acids 196 to 225 (5a). This peptide was found to react with many of the Lyme disease sera from patients with late-stage disease, in agreement with Schneider et al. Berland et al. (1) also found that the immunodominant domain comprising amino acids 197 to 241 was bound by serum samples from 17 to 18 patients exhibiting manifestations of late-stage disease. In a subsequent study (3), they determined that the majority of sera from Lyme disease patients with arthritis and neuroborreliosis contained antibodies that bound to the region encompassing amino acids 208 to 225. However, we also observed that patients with arthritic manifestations had antibodies reactive with the region defined by amino acids 1 to 137, which agrees with the results obtained by Collins and Peltz (2). Jiang et al. (5) also demonstrated that in addition to the dominant epitopes in the central portion of flagellin, additional Lyme serum-reactive epitopes were identified in the amino-terminal region.
The specificity of serodiagnosis of Lyme disease will certainly be improved through the use of specific regions of the flagellin. The question remains regarding the ability of such a target to detect all cases of Lyme disease. Additional specific B. burgdorferi proteins such as OspA, OspC, the 39-kDa protein, and others will need to be-evaluated as to their role in the diagnosis of Lyme disease.
